Safety and Efficacy of Cariprazine in Schizophrenia

Inclusion Criteria:

- Patients who have provided informed consent prior to any study specific procedures

- Patients currently meeting the Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia (paranoid type,
disorganized type, catatonic type or undifferentiated type), as confirmed by the
Structured Clinical Interview for Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (SCID)

- Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCIPANSS)
total score ≥ 80 and ≤ 120

- Diagnosis of schizophrenia for a minimum of 1 year before Visit 1

- Patients with normal physical examination, laboratory, vital signs,and/ or
electrocardiogram (ECG)

Exclusion Criteria:

- Patients with a DSM-IV-TR diagnosis of Schizoaffective disorder, schizophreniform
disorder, other psychotic disorders other than schizophrenia, or bipolar I or II
disorder

- Patients in their first episode of psychosis

- Pregnant, breast-feeding, and/or planning to become pregnant and/or breastfeed during
the study

- Pervasive developmental disorder, mental retardation, delirium, dementia, amnestic and
other cognitive disorders

- Known or suspected borderline or antisocial personality disorder or other DSM-IV-TR
axis II disorder of sufficient severity to interfere with participation in this study

- Substance abuse or dependence within the prior 3 months